Inhibition of islet immunoreactivity by adiponectin is attenuated in human type 1 diabetes. by Pang, T, Chimen, M, Goble, E, Dixon, N, Benbow, A, Eldershaw, SE, Thompson, D, Gough, S, Narendran, P

PEPITEM modulates leukocyte trafficking to reduce obesity-induced inflammation by Pezhman, L, Hopkin, S, Begum, J, Heising, S, Wahid, M, Rainger, GE, Hodson, DJ, Iqbal, A, Chimen, M, McGettrick, H

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells by Carretero-Iglesia, L, Hall, OJ, Berret, J, Pais, D, Estoppey, C, Chimen, M, Monney, T, Loyau, J, Dreyfus, C, Macoin, J, Perez, C, Menon, V, Gruber, I, Laurendon, A, Caro, LN, Gudi, GS, Matsuura, T, van der Graaf, PH, Blein, S, Mbow, ML, Croasdale-Wood, R, Srivastava, A, Dyson, MR, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma by Grandclément, C, Estoppey, C, Dheilly, E, Panagopoulou, M, Monney, T, Dreyfus, C, Loyau, J, Labanca, V, Drake, A, De Angelis, S, Rubod, A, Frei, J, Caro, LN, Blein, S, Martini, E, Chimen, M, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR, Menoret, E, Kervoelen, C, Pellat-Deceunynck, C, Moreau, P, Mbow, ML, Srivastava, A, Dyson, MR, Zhukovsky, EA, Perro, M, Sammicheli, S

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma by Pouleau, B, Estoppey, C, Suere, P, Nallet, E, Laurendon, A, Monney, T, Pais Ferreira, D, Drake, A, Carretero-Iglesia, L, Macoin, J, Berret, J, Pihlgren, M, Doucey, M-A, Gudi, GS, Menon, V, Udupa, V, Maiti, A, Borthakur, G, Srivastava, A, Blein, S, Mbow, ML, Matthes, T, Kaya, Z, Edwards, C, Edwards, JR, Menoret, E, Kervoëlen, C, Pellat-Deceunynck, C, Moreau, P, Zhukovsky, E, Perro, M, Chimen, M